Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

celularity inc. - CELU

CELU

Close Chg Chg %
1.00 -0.12 -12.33%

Closed Market

0.87

-0.12 (12.33%)

Volume: 34.25K

Last Updated:

Jun 5, 2026, 4:00 PM EDT

Trade Now

Company Overview: celularity inc. - CELU

CELU Key Data

Open

$0.97

 Day Range

0.87 - 1.02

52 Week Range

0.71 - 4.35

 Market Cap

$28.95M

Shares Outstanding

28.95M

 Public Float

11.57M

Beta

0.48

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$3.58

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

148.28K

  

CELU Performance

1 Week
 
 -13.63%
 
1 Month
 
 -0.86%
 
3 Months
 
 -27.91%
 
1 Year
 
 -58.06%
 
5 Years
 
 -99.14%
 

CELU Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About celularity inc. - CELU

Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.

CELU At a Glance

Celularity, Inc.
170 Park Avenue
Florham Park, New Jersey 07932
Phone 1-908-768-2170 Revenue 26.55M
Industry Miscellaneous Commercial Services Net Income -91,716,000.00
Sector Commercial Services Employees 115
Fiscal Year-end 12 / 2026
View SEC Filings

CELU Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.07
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.795
Enterprise Value to Sales 3.652
Total Debt to Enterprise Value 0.771

CELU Efficiency

Revenue/Employee 230,869.565
Income Per Employee -797,530.435
Receivables Turnover 5.706
Total Asset Turnover 0.086

CELU Liquidity

Current Ratio 0.153
Quick Ratio 0.145
Cash Ratio 0.076

CELU Profitability

Gross Margin -3.085
Operating Margin -230.911
Pretax Margin -345.435
Net Margin -345.446
Return on Assets -29.73
Return on Equity N/A
Return on Total Capital -250.241
Return on Invested Capital -199.715

CELU Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 203.85
Total Debt to Total Assets 24.666
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 159.878
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Celularity Inc. - CELU

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
17.98M 22.77M 54.22M 26.55M
Sales Growth
-15.75% +26.68% +138.11% -51.03%
Cost of Goods Sold (COGS) incl D&A
29.10M 25.34M 22.91M 27.37M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
9.38M 9.32M 7.92M 7.29M
Depreciation
7.18M 7.13M 6.17M 5.80M
Amortization of Intangibles
2.19M 2.19M 1.75M 1.49M
COGS Growth
+57.56% -12.92% -9.59% +19.46%
Gross Income
(11.13M) (2.57M) 31.31M (819.00K)
Gross Income Growth
-488.34% +76.91% +1,318.72% -102.62%
Gross Profit Margin
-61.90% -11.28% +57.74% -3.08%
2022 2023 2024 2025 5-year trend
SG&A Expense
137.14M 73.91M 69.86M 60.49M
Research & Development
71.12M 23.33M 11.22M 9.22M
Other SG&A
66.02M 50.58M 58.64M 51.27M
SGA Growth
-10.41% -46.11% -5.48% -13.42%
Other Operating Expense
- - - -
-
Unusual Expense
(162.07M) 110.82M 3.81M 14.31M
EBIT after Unusual Expense
13.80M (187.30M) (42.36M) (75.62M)
Non Operating Income/Expense
404.00K (5.97M) (9.27M) (9.34M)
Non-Operating Interest Income
365.00K 320.00K 331.00K 262.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 3.02M 6.26M 6.75M
Interest Expense Growth
- - +107.76% +7.82%
-
Gross Interest Expense
- 3.02M 6.26M 6.75M
Interest Capitalized
- - - -
-
Pretax Income
14.21M (196.28M) (57.89M) (91.71M)
Pretax Income Growth
+114.19% -1,481.80% +70.51% -58.42%
Pretax Margin
+79.03% -862.00% -106.77% -345.44%
Income Tax
- 13.00K 10.00K 3.00K
Income Tax - Current - Domestic
- - 13.00K 10.00K
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - 3.00K
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
14.19M (196.29M) (57.89M) (91.72M)
Minority Interest Expense
- - - -
-
Net Income
14.19M (196.29M) (57.89M) (91.72M)
Net Income Growth
+114.18% -1,483.14% +70.51% -58.43%
Net Margin Growth
+78.95% -862.04% -106.77% -345.45%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
14.19M (196.29M) (57.89M) (91.72M)
Preferred Dividends
- - - 84.00K
-
Net Income Available to Common
14.19M (196.29M) (57.89M) (91.80M)
EPS (Basic)
1.0144 -11.0197 -2.6446 -3.5861
EPS (Basic) Growth
+106.79% -1,186.33% +76.00% -35.60%
Basic Shares Outstanding
13.99M 17.81M 21.89M 25.60M
EPS (Diluted)
0.9472 -11.0197 -2.6446 -3.5861
EPS (Diluted) Growth
+106.34% -1,263.40% +76.00% -35.60%
Diluted Shares Outstanding
14.98M 17.81M 21.89M 25.60M
EBITDA
(138.89M) (67.16M) (30.63M) (54.01M)
EBITDA Growth
+1.77% +51.65% +54.39% -76.34%
EBITDA Margin
-772.68% -294.91% -56.49% -203.44%

Insider Actions for Celularity Inc. - CELU

Date Name Shares Transaction Value
Apr 16, 2026 Stephen A. Brigido Pres., Functional Regeneration N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 16, 2026 Stephen A. Brigido Pres., Functional Regeneration 9,474 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.28 per share 12,126.72
Apr 16, 2026 Stephen A. Brigido Pres., Functional Regeneration 9,742 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 16, 2026 John R. Haines Senior Exec Vice President N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 16, 2026 John R. Haines Senior Exec Vice President 30,179 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.28 per share 38,629.12
Apr 16, 2026 John R. Haines Senior Exec Vice President 30,762 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 16, 2026 Robert Joseph Hariri Gordon Chief Executive Officer; Director 2,854,735 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 16, 2026 Robert Joseph Hariri Gordon Chief Executive Officer; Director 2,853,553 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.28 per share 3,652,547.84
Apr 16, 2026 Robert Joseph Hariri Gordon Chief Executive Officer; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 16, 2026 Vincent LeVien Director 153,847 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 16, 2026 Shiu Fei Ling Director 256,026 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 16, 2026 Diane L. Parks Director 520,021 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 16, 2026 Peter H. Diamandis Director 394,150 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Kok Thay Lim 3,700,000 Other acquisition or disposition 0.00
Jul 29, 2025 Genting Bhd. 500,000 Other acquisition or disposition 0.00
Jul 29, 2025 Genting Bhd. 1,350,000 Other acquisition or disposition 0.00
Jul 29, 2025 Genting Bhd. N/A Other acquisition or disposition 0.00
Jul 29, 2025 Genting Bhd. 300,000 Other acquisition or disposition 0.00
Jul 29, 2025 Genting Bhd. N/A Other acquisition or disposition 0.00
Jul 29, 2025 Genting Bhd. 300,000 Other acquisition or disposition 0.00

Celularity Inc. in the News